Background:
Epidermal growth factor receptor (EGFR, ErBb) belongs to family of receptor tyrosine kinase (RTKs) played important role in multiple cell signaling pathways, which includes cell growth, multiplication and apoptosis etc. Overexpression of EGFR results in to development of malignant cells. Therefore EGFR considered as one of the important target for cancer therapy.
Objective:
In this study we performed virtual screening of 329 flavonoids obtained from Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target (NPACT) database to identify novel EGFR inhibitors.
Materials and methods:
Virtual screening carried out using different insilico methods which includes molecular docking studies, prediction of druglikeness, insilico toxicity studies and bioactivity prediction.
Results:
Six flavonoids NPACT00061, NPACT00062, NPACT00066, NPACT00280, NPACT00700 and NPACT00856 were identified as potential EGFR inhibitors with good docking score and druglikeness properties. In the insilico toxicity studies, compound NPACT00061, NPACT00062, NPACT00066 and NPACT00856 were found to be carcinogenic. Finally, two flavonoids NPACT00280 and NPACT00700 were recognized as novel EGFR inhibitors. Conclusion: Our findings suggest that compound NPACT00280 and NPACT00700 could be further explored as novel EGFR inhibitors.
Discovery of novel human epidermal growth factor Receptor-2 inhibitors by structure-based virtual screening
